• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    2/24/23 4:31:08 PM ET
    $ASLN
    $AVDL
    $AWH
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASLN alert in real time by email

    Gainers

    • Lucira Health (NASDAQ:LHDX) stock increased by 65.1% to $0.23 during Friday's after-market session. This security traded at a volume of 15.2 million shares come close, making up 248.3% of its average volume over the last 100 days. The company's market cap stands at $9.3 million.
    • Lixte Biotech Hldgs (NASDAQ:LIXT) shares increased by 11.95% to $0.94. The market value of their outstanding shares is at $15.6 million.
    • T2 Biosystems (NASDAQ:TTOO) shares increased by 6.3% to $0.6. The company's market cap stands at $9.7 million.
    • Biofrontera (NASDAQ:BFRI) stock increased by 5.27% to $0.79. The company's market cap stands at $21.0 million.
    • Aspira Womens Health (NASDAQ:AWH) stock rose 5.0% to $0.46. The market value of their outstanding shares is at $57.5 million.
    • Harpoon Therapeutics (NASDAQ:HARP) shares rose 5.0% to $0.78. The company's market cap stands at $25.8 million.

    Losers

    • Kiromic BioPharma (NASDAQ:KRBP) stock declined by 7.8% to $0.16 during Friday's after-market session. Trading volume for this security closed at 145.4K, accounting for 10.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.2 million.
    • Prenetics Global (NASDAQ:PRE) stock fell 6.87% to $0.95. The market value of their outstanding shares is at $112.8 million.
    • Midatech Pharma (NASDAQ:MTP) stock fell 6.32% to $0.5. The market value of their outstanding shares is at $3.4 million.
    • ASLAN Pharma (NASDAQ:ASLN) stock decreased by 5.01% to $0.8. Today's trading volume for this security ended up closing at 113.2K shares, which is 68.5 percent of its average volume over the last 100 days. The company's market cap stands at $55.4 million.
    • GeneDx Holdings (NASDAQ:WGS) shares decreased by 5.0% to $0.48. Today's trading volume for this security ended up closing at 72.7K shares, which is 1.9 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $376.8 million.
    • Avadel Pharmaceuticals (NASDAQ:AVDL) shares decreased by 4.65% to $9.03. The market value of their outstanding shares is at $557.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ASLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASLN
    $AVDL
    $AWH
    $BFRI

    CompanyDatePrice TargetRatingAnalyst
    Prenetics Global Limited
    $PRE
    3/16/2026$29.00Buy
    Lake Street
    Prenetics Global Limited
    $PRE
    2/11/2026$36.00Buy
    Roth Capital
    GeneDx Holdings Corp.
    $WGS
    2/9/2026$155.00Equal Weight → Overweight
    Wells Fargo
    Avadel Pharmaceuticals plc
    $AVDL
    10/23/2025$20.00Buy → Neutral
    H.C. Wainwright
    GeneDx Holdings Corp.
    $WGS
    10/20/2025$155.00Buy
    Canaccord Genuity
    Avadel Pharmaceuticals plc
    $AVDL
    9/3/2025$16.00Equal Weight
    Wells Fargo
    Avadel Pharmaceuticals plc
    $AVDL
    7/18/2025$22.00Buy
    H.C. Wainwright
    GeneDx Holdings Corp.
    $WGS
    7/9/2025$110.00Overweight
    Piper Sandler
    More analyst ratings

    $ASLN
    $AVDL
    $AWH
    $BFRI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Meister Keith A. bought $13,460,090 worth of shares (169,521 units at $79.40) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/5/26 7:19:34 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Meister Keith A. bought $3,007,997 worth of shares (50,000 units at $60.16) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    5/16/25 4:00:06 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Meister Keith A. bought $5,600,994 worth of shares (100,000 units at $56.01) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    5/12/25 7:46:55 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $ASLN
    $AVDL
    $AWH
    $BFRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Prenetics Group Ltd. with a new price target

    Lake Street initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $29.00

    3/16/26 8:45:09 AM ET
    $PRE
    Blank Checks
    Finance

    Roth Capital initiated coverage on Prenetics Group Ltd. with a new price target

    Roth Capital initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $36.00

    2/11/26 7:52:37 AM ET
    $PRE
    Blank Checks
    Finance

    GeneDx upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded GeneDx from Equal Weight to Overweight and set a new price target of $155.00

    2/9/26 6:58:22 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $ASLN
    $AVDL
    $AWH
    $BFRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Cheng Yin Pan

    3 - Prenetics Global Ltd (0001876431) (Issuer)

    3/24/26 10:30:07 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form 3 filed by new insider Lo Hoi Chun

    3 - Prenetics Global Ltd (0001876431) (Issuer)

    3/18/26 11:17:48 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form 3 filed by Prenetics Global Limited

    3 - Prenetics Global Ltd (0001876431) (Issuer)

    3/18/26 11:02:27 AM ET
    $PRE
    Blank Checks
    Finance

    $ASLN
    $AVDL
    $AWH
    $BFRI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prenetics' IM8 Partners with Superpower to Personalize the Future of Supplementation

    IM8 90-Day Subscribers Unlock SuperPower Blood Testing for $49 — A 75% Saving on the Standard $199 Price.IM8 and Superpower create the first closed-loop system in consumer health – connecting clinical-grade supplementation with 100+ biomarker blood testing.IM8's Daily Ultimate Essentials will be available in the Superpower supplement marketplace and featured, where biomarker data supports it, as one of Superpower's recommended foundational daily supplements in members' personalized health protocols. NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium heal

    3/24/26 11:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update. Fourth Quarter Financial Highlights Revenues for 4Q25 were a record $17.1 million, a 36% increase compared to $12.6 million for the same period in 2024.Gross margins were 82.4%, a roughly 2,400 basis point year over year increase compared to 58.0% in 4Q24, reflecting the transitio

    3/19/26 9:25:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prenetics to Participate in the 38th Annual ROTH Conference

    NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today announced the Company will participate in the 38th Annual ROTH Conference being held Sunday, March 22nd to Tuesday, March 24th at the Ritz-Carlton in Laguna Niguel, CA. Prenetics CEO Danny Yeung and President of Americas David Vanderveen will be available for one-on-one meetings throughout the conference. Management will also participate in a fireside chat at 8:30 a.m. PT and a Consumer Influencer panel discussion at 12:00 p.m. PT on Monday, March 23rd — both available via webc

    3/18/26 8:30:00 AM ET
    $PRE
    Blank Checks
    Finance

    $ASLN
    $AVDL
    $AWH
    $BFRI
    SEC Filings

    View All

    Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

    3/20/26 4:05:18 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Biofrontera Inc.

    10-K - Biofrontera Inc. (0001858685) (Filer)

    3/19/26 4:15:56 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Biofrontera Inc. (0001858685) (Filer)

    3/19/26 9:35:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $AVDL
    $AWH
    $BFRI
    Leadership Updates

    Live Leadership Updates

    View All

    LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

    BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company's Liora Technologies Europe Ltd. subsidiary ("Liora"). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc. Over his

    2/18/26 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Formula 1 Phenom Ollie Bearman Joins Prenetics' IM8 Health as Global Ambassador and Shareholder

    Ollie Bearman becomes the latest elite athlete to invest in NASDAQ:PRE, underscoring a deep belief in the brand's mission and products.IM8, co-founded by David Beckham, continues to attract top-tier athletes who prioritize scientifically validated and trusted nutritional support.IM8 has become one of the fastest-growing supplement brands globally, achieving an extraordinary US$100 million in Annual Recurring Revenue in just 11 months from launch.Bearman's rapid rise – including a historic points-scoring Ferrari debut at just 18—cements his reputation as one of motorsport's brightest young talents. NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading

    2/13/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

    Recognized neonatologist and payer-strategy leader joins GeneDx to expand earlier diagnosis and establish genomics as a standard of care across healthcare GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights today announced Linda Genen, MD, MPH as Chief Medical Officer to further strengthen the company's commitment to delivering earlier answers and better outcomes for families through genomic insights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106493899/en/GeneDx Names Dr. Linda Genen, MD, MPH as Chief Medical Officer In her role at GeneDx, Dr. Genen will oversee Medical and Cli

    1/6/26 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $ASLN
    $AVDL
    $AWH
    $BFRI
    Financials

    Live finance-specific insights

    View All

    Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update. Fourth Quarter Financial Highlights Revenues for 4Q25 were a record $17.1 million, a 36% increase compared to $12.6 million for the same period in 2024.Gross margins were 82.4%, a roughly 2,400 basis point year over year increase compared to 58.0% in 4Q24, reflecting the transitio

    3/19/26 9:25:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

    WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Busi

    3/9/26 5:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

    Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit) Accelerated exome and genome volume growth to 34% year-over-year Reported fourth quarter 2025 adjusted gross margin1 of 71% Reported fourth quarter 2025 adjusted net income1 of $4.4 million Reaffirmed full year 2026 guidance of $540 to $555 million in revenue with 33-35% exome and genome growth GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for t

    2/23/26 6:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $ASLN
    $AVDL
    $AWH
    $BFRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/20/24 9:36:13 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/19/24 8:00:24 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: SEC Form SC 13G/A filed by Biofrontera Inc.

    SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

    11/14/24 3:54:03 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care